Thomas Jaenisch
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dengue | 24 | 2023 | 59 | 5.740 |
Why?
| Zika Virus Infection | 25 | 2023 | 85 | 5.510 |
Why?
| Zika Virus | 21 | 2023 | 61 | 3.050 |
Why?
| Pregnancy Complications, Infectious | 12 | 2022 | 288 | 2.350 |
Why?
| Microcephaly | 9 | 2023 | 51 | 1.640 |
Why?
| Epidemics | 4 | 2023 | 69 | 1.180 |
Why?
| Dengue Virus | 11 | 2023 | 31 | 1.160 |
Why?
| Disease Outbreaks | 8 | 2022 | 307 | 1.010 |
Why?
| Malaria | 3 | 2022 | 48 | 1.000 |
Why?
| Antibodies, Viral | 13 | 2023 | 520 | 0.870 |
Why?
| Congenital Abnormalities | 2 | 2021 | 73 | 0.840 |
Why?
| Malaria, Falciparum | 3 | 2012 | 25 | 0.810 |
Why?
| Protein Array Analysis | 2 | 2020 | 56 | 0.800 |
Why?
| Masks | 1 | 2022 | 46 | 0.800 |
Why?
| Chikungunya Fever | 7 | 2023 | 61 | 0.790 |
Why?
| Brazil | 14 | 2023 | 89 | 0.780 |
Why?
| Endpoint Determination | 2 | 2018 | 68 | 0.770 |
Why?
| Anemia | 3 | 2022 | 143 | 0.730 |
Why?
| Dengue Vaccines | 2 | 2018 | 9 | 0.680 |
Why?
| Seroepidemiologic Studies | 12 | 2023 | 138 | 0.670 |
Why?
| Communicable Diseases | 4 | 2022 | 129 | 0.670 |
Why?
| Epitopes, B-Lymphocyte | 1 | 2019 | 16 | 0.640 |
Why?
| Severe Dengue | 5 | 2022 | 9 | 0.620 |
Why?
| Clinical Trials as Topic | 2 | 2018 | 931 | 0.570 |
Why?
| Plasmodium falciparum | 3 | 2019 | 27 | 0.570 |
Why?
| Parasitemia | 2 | 2021 | 9 | 0.540 |
Why?
| Latin America | 7 | 2023 | 69 | 0.530 |
Why?
| Humans | 74 | 2023 | 114662 | 0.520 |
Why?
| Child Health | 1 | 2016 | 127 | 0.480 |
Why?
| Prospective Studies | 16 | 2023 | 6219 | 0.480 |
Why?
| Capital Financing | 1 | 2013 | 5 | 0.450 |
Why?
| Peptides | 1 | 2019 | 848 | 0.440 |
Why?
| Young Adult | 20 | 2023 | 10466 | 0.410 |
Why?
| Child | 24 | 2023 | 18412 | 0.410 |
Why?
| Genetic Variation | 2 | 2017 | 870 | 0.400 |
Why?
| Chikungunya virus | 6 | 2023 | 61 | 0.390 |
Why?
| Biomedical Research | 2 | 2016 | 585 | 0.390 |
Why?
| Mosquito Vectors | 4 | 2019 | 21 | 0.370 |
Why?
| Female | 37 | 2023 | 59493 | 0.370 |
Why?
| Emergency Responders | 2 | 2021 | 33 | 0.360 |
Why?
| Pregnancy | 13 | 2022 | 5518 | 0.360 |
Why?
| Bayes Theorem | 2 | 2022 | 329 | 0.350 |
Why?
| Hemoglobins | 2 | 2022 | 315 | 0.340 |
Why?
| Aedes | 4 | 2019 | 55 | 0.340 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2021 | 152 | 0.340 |
Why?
| Alphavirus | 2 | 2019 | 17 | 0.340 |
Why?
| Delivery of Health Care | 1 | 2016 | 833 | 0.330 |
Why?
| Alphavirus Infections | 2 | 2019 | 41 | 0.320 |
Why?
| Adolescent | 18 | 2023 | 17841 | 0.310 |
Why?
| Serologic Tests | 4 | 2021 | 49 | 0.300 |
Why?
| Asia | 5 | 2023 | 53 | 0.300 |
Why?
| Male | 28 | 2023 | 55583 | 0.300 |
Why?
| Adult | 23 | 2023 | 30544 | 0.300 |
Why?
| Incidence | 7 | 2020 | 2313 | 0.290 |
Why?
| Infant, Newborn | 12 | 2022 | 5045 | 0.290 |
Why?
| Infant | 11 | 2021 | 7961 | 0.290 |
Why?
| Immunity, Humoral | 2 | 2019 | 112 | 0.280 |
Why?
| Pneumonia | 1 | 2012 | 567 | 0.280 |
Why?
| Virus Diseases | 2 | 2019 | 195 | 0.270 |
Why?
| Cluster Analysis | 2 | 2019 | 455 | 0.260 |
Why?
| Africa South of the Sahara | 2 | 2022 | 34 | 0.240 |
Why?
| Child, Preschool | 13 | 2023 | 9114 | 0.240 |
Why?
| Fever | 2 | 2023 | 280 | 0.240 |
Why?
| Severity of Illness Index | 2 | 2014 | 2538 | 0.240 |
Why?
| Middle Aged | 15 | 2023 | 26733 | 0.230 |
Why?
| Malaria Vaccines | 2 | 2019 | 6 | 0.230 |
Why?
| Viral Nonstructural Proteins | 2 | 2018 | 54 | 0.230 |
Why?
| Attitude of Health Personnel | 1 | 2011 | 975 | 0.230 |
Why?
| Risk Factors | 10 | 2022 | 8632 | 0.220 |
Why?
| Linear Models | 2 | 2023 | 768 | 0.220 |
Why?
| Molecular Diagnostic Techniques | 2 | 2021 | 91 | 0.210 |
Why?
| O'nyong-nyong Virus | 2 | 2019 | 4 | 0.210 |
Why?
| Antibodies, Neutralizing | 2 | 2022 | 221 | 0.210 |
Why?
| Cytokines | 3 | 2021 | 1840 | 0.210 |
Why?
| Algorithms | 2 | 2022 | 1468 | 0.210 |
Why?
| RNA, Viral | 4 | 2022 | 565 | 0.210 |
Why?
| Oligohydramnios | 1 | 2022 | 8 | 0.200 |
Why?
| Toxoplasmosis | 2 | 2019 | 31 | 0.200 |
Why?
| Ebolavirus | 1 | 2022 | 34 | 0.200 |
Why?
| Personal Protective Equipment | 1 | 2022 | 49 | 0.200 |
Why?
| Mosquito Control | 2 | 2014 | 24 | 0.200 |
Why?
| Observational Studies as Topic | 1 | 2022 | 90 | 0.200 |
Why?
| World Health Organization | 4 | 2018 | 102 | 0.200 |
Why?
| Tanzania | 2 | 2012 | 41 | 0.190 |
Why?
| Epitopes | 2 | 2020 | 435 | 0.190 |
Why?
| Sexually Transmitted Diseases, Viral | 1 | 2021 | 7 | 0.190 |
Why?
| Health Policy | 2 | 2014 | 334 | 0.180 |
Why?
| Prevalence | 4 | 2021 | 2251 | 0.180 |
Why?
| Chemokine CXCL10 | 1 | 2021 | 34 | 0.180 |
Why?
| Biomarkers | 5 | 2023 | 3408 | 0.180 |
Why?
| Politics | 1 | 2021 | 79 | 0.180 |
Why?
| Hospitalization | 2 | 2020 | 1751 | 0.180 |
Why?
| Risk | 5 | 2021 | 812 | 0.180 |
Why?
| Epitope Mapping | 1 | 2020 | 51 | 0.180 |
Why?
| Case-Control Studies | 4 | 2021 | 3003 | 0.180 |
Why?
| Transients and Migrants | 1 | 2020 | 22 | 0.170 |
Why?
| Rubella virus | 1 | 2019 | 6 | 0.170 |
Why?
| Arboviruses | 1 | 2019 | 10 | 0.170 |
Why?
| Parvovirus B19, Human | 1 | 2019 | 3 | 0.170 |
Why?
| Emigration and Immigration | 1 | 2020 | 44 | 0.170 |
Why?
| Hydrocephalus | 1 | 2020 | 83 | 0.170 |
Why?
| Research Design | 2 | 2023 | 928 | 0.170 |
Why?
| Toxoplasma | 1 | 2019 | 31 | 0.170 |
Why?
| Phylogeny | 3 | 2019 | 789 | 0.170 |
Why?
| Sexual Partners | 1 | 2021 | 161 | 0.160 |
Why?
| Diagnosis, Differential | 3 | 2021 | 1342 | 0.160 |
Why?
| Violence | 1 | 2021 | 202 | 0.160 |
Why?
| Viral Load | 1 | 2021 | 405 | 0.160 |
Why?
| Antibodies, Protozoan | 1 | 2019 | 30 | 0.160 |
Why?
| Premature Birth | 1 | 2022 | 276 | 0.160 |
Why?
| Pandemics | 3 | 2022 | 1317 | 0.160 |
Why?
| Cytomegalovirus | 1 | 2019 | 144 | 0.160 |
Why?
| Africa | 2 | 2019 | 94 | 0.160 |
Why?
| Automation | 1 | 2019 | 73 | 0.160 |
Why?
| Genotype | 4 | 2017 | 1760 | 0.160 |
Why?
| Peptide Library | 1 | 2019 | 81 | 0.160 |
Why?
| Communicable Diseases, Emerging | 1 | 2018 | 28 | 0.150 |
Why?
| Global Health | 3 | 2019 | 287 | 0.150 |
Why?
| Serotyping | 1 | 2018 | 28 | 0.150 |
Why?
| Delphi Technique | 1 | 2018 | 160 | 0.150 |
Why?
| Longitudinal Studies | 4 | 2022 | 2387 | 0.150 |
Why?
| Serum | 1 | 2018 | 57 | 0.150 |
Why?
| C-Reactive Protein | 1 | 2020 | 362 | 0.150 |
Why?
| Phosphoinositide Phospholipase C | 1 | 2017 | 4 | 0.140 |
Why?
| Maternal-Fetal Exchange | 1 | 2018 | 151 | 0.140 |
Why?
| Vietnam | 3 | 2023 | 21 | 0.140 |
Why?
| Nucleic Acid Amplification Techniques | 1 | 2017 | 34 | 0.140 |
Why?
| Blood Donors | 1 | 2018 | 89 | 0.140 |
Why?
| Cohort Studies | 6 | 2020 | 4895 | 0.140 |
Why?
| Peptide Mapping | 1 | 2017 | 60 | 0.140 |
Why?
| Endemic Diseases | 2 | 2014 | 23 | 0.140 |
Why?
| Sequence Homology | 1 | 2016 | 39 | 0.130 |
Why?
| Caribbean Region | 3 | 2020 | 19 | 0.130 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 797 | 0.130 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 172 | 0.130 |
Why?
| Viral Envelope Proteins | 1 | 2016 | 73 | 0.130 |
Why?
| Clinical Protocols | 1 | 2016 | 233 | 0.120 |
Why?
| Antigens | 1 | 2017 | 318 | 0.120 |
Why?
| Serogroup | 3 | 2021 | 26 | 0.120 |
Why?
| Fluid Therapy | 1 | 2016 | 123 | 0.120 |
Why?
| Animals | 11 | 2019 | 31699 | 0.120 |
Why?
| Mental Health | 1 | 2020 | 562 | 0.120 |
Why?
| Residence Characteristics | 1 | 2017 | 275 | 0.120 |
Why?
| Reproducibility of Results | 2 | 2019 | 2763 | 0.120 |
Why?
| Antibodies | 1 | 2017 | 371 | 0.120 |
Why?
| Models, Theoretical | 1 | 2018 | 515 | 0.120 |
Why?
| Antigens, Viral | 2 | 2018 | 176 | 0.120 |
Why?
| Environment | 1 | 2016 | 332 | 0.110 |
Why?
| European Union | 1 | 2013 | 8 | 0.110 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2021 | 758 | 0.110 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 723 | 0.110 |
Why?
| Immunoglobulin M | 3 | 2021 | 246 | 0.110 |
Why?
| Disease Management | 1 | 2016 | 560 | 0.100 |
Why?
| Sensitivity and Specificity | 4 | 2019 | 1692 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2021 | 4411 | 0.090 |
Why?
| Peru | 2 | 2021 | 54 | 0.090 |
Why?
| Causality | 2 | 2022 | 103 | 0.090 |
Why?
| Mass Screening | 1 | 2018 | 1004 | 0.090 |
Why?
| Inflammation | 1 | 2021 | 2478 | 0.090 |
Why?
| Virology | 1 | 2010 | 19 | 0.090 |
Why?
| Reagent Kits, Diagnostic | 1 | 2010 | 42 | 0.090 |
Why?
| Age Factors | 2 | 2020 | 2894 | 0.090 |
Why?
| Cross Reactions | 2 | 2022 | 117 | 0.090 |
Why?
| Indian Ocean Islands | 1 | 2010 | 1 | 0.090 |
Why?
| Family Characteristics | 2 | 2021 | 151 | 0.090 |
Why?
| Neutralization Tests | 2 | 2021 | 63 | 0.090 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 1879 | 0.090 |
Why?
| Rural Health | 1 | 2010 | 67 | 0.080 |
Why?
| Focus Groups | 1 | 2011 | 383 | 0.080 |
Why?
| Age Distribution | 1 | 2010 | 342 | 0.080 |
Why?
| Surveys and Questionnaires | 2 | 2011 | 4622 | 0.080 |
Why?
| Americas | 2 | 2019 | 19 | 0.080 |
Why?
| Viremia | 2 | 2021 | 122 | 0.080 |
Why?
| Coinfection | 2 | 2019 | 120 | 0.080 |
Why?
| Multivariate Analysis | 1 | 2012 | 1430 | 0.080 |
Why?
| Risk Assessment | 1 | 2017 | 2968 | 0.070 |
Why?
| Genome, Viral | 2 | 2019 | 118 | 0.070 |
Why?
| Spatio-Temporal Analysis | 2 | 2017 | 25 | 0.070 |
Why?
| Antigens, Protozoan | 1 | 2007 | 19 | 0.070 |
Why?
| High-Throughput Screening Assays | 2 | 2020 | 123 | 0.070 |
Why?
| Public Health | 3 | 2017 | 433 | 0.070 |
Why?
| Logistic Models | 1 | 2012 | 1841 | 0.070 |
Why?
| Prenatal Care | 2 | 2019 | 253 | 0.070 |
Why?
| Immunoglobulin G | 2 | 2021 | 770 | 0.070 |
Why?
| Microsatellite Repeats | 1 | 2007 | 136 | 0.070 |
Why?
| Urbanization | 2 | 2019 | 24 | 0.070 |
Why?
| Aged | 6 | 2023 | 19069 | 0.070 |
Why?
| Tropical Climate | 2 | 2016 | 17 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2022 | 1214 | 0.060 |
Why?
| Polymorphism, Genetic | 1 | 2007 | 610 | 0.060 |
Why?
| Altitude | 1 | 2007 | 432 | 0.050 |
Why?
| Bangladesh | 1 | 2023 | 31 | 0.050 |
Why?
| Burkina Faso | 1 | 2021 | 3 | 0.050 |
Why?
| Middle East | 1 | 2021 | 10 | 0.050 |
Why?
| Colostrum | 1 | 2021 | 2 | 0.050 |
Why?
| Colorado | 2 | 2021 | 4099 | 0.050 |
Why?
| Venezuela | 1 | 2021 | 7 | 0.050 |
Why?
| Publication Bias | 1 | 2021 | 36 | 0.050 |
Why?
| Disease Progression | 2 | 2020 | 2380 | 0.050 |
Why?
| Amniotic Fluid | 1 | 2021 | 64 | 0.050 |
Why?
| Pregnant Women | 1 | 2022 | 131 | 0.050 |
Why?
| Pregnancy Trimesters | 1 | 2021 | 13 | 0.050 |
Why?
| Microspheres | 1 | 2021 | 123 | 0.050 |
Why?
| Immunoassay | 1 | 2021 | 95 | 0.050 |
Why?
| Cross-Sectional Studies | 2 | 2021 | 4408 | 0.050 |
Why?
| Blood | 1 | 2021 | 96 | 0.050 |
Why?
| Immunomodulation | 1 | 2021 | 84 | 0.040 |
Why?
| Parturition | 1 | 2020 | 54 | 0.040 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 313 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2022 | 337 | 0.040 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 87 | 0.040 |
Why?
| Disease Reservoirs | 1 | 2019 | 18 | 0.040 |
Why?
| Genes, Viral | 1 | 2019 | 89 | 0.040 |
Why?
| Geography, Medical | 1 | 2019 | 10 | 0.040 |
Why?
| Zoonoses | 1 | 2019 | 21 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2019 | 26 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2021 | 6345 | 0.040 |
Why?
| Primates | 1 | 2019 | 111 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2021 | 993 | 0.040 |
Why?
| Meta-Analysis as Topic | 1 | 2019 | 158 | 0.040 |
Why?
| Computer Simulation | 1 | 2022 | 872 | 0.040 |
Why?
| Bolivia | 1 | 2018 | 62 | 0.040 |
Why?
| Kinetics | 1 | 2021 | 1551 | 0.040 |
Why?
| Time Factors | 2 | 2020 | 6115 | 0.040 |
Why?
| Viral Plaque Assay | 1 | 2017 | 24 | 0.040 |
Why?
| Parent-Child Relations | 1 | 2020 | 235 | 0.040 |
Why?
| Volunteers | 1 | 2018 | 31 | 0.040 |
Why?
| Iron | 1 | 2019 | 233 | 0.040 |
Why?
| Climate Change | 1 | 2019 | 120 | 0.040 |
Why?
| Basic Reproduction Number | 1 | 2017 | 3 | 0.040 |
Why?
| Betacoronavirus | 1 | 2020 | 250 | 0.040 |
Why?
| Poliovirus Vaccines | 1 | 2017 | 3 | 0.040 |
Why?
| Binding Sites, Antibody | 1 | 2017 | 36 | 0.040 |
Why?
| Culicidae | 1 | 2017 | 29 | 0.040 |
Why?
| Phylogeography | 1 | 2017 | 44 | 0.040 |
Why?
| Molecular Epidemiology | 1 | 2017 | 62 | 0.030 |
Why?
| Cell Surface Display Techniques | 1 | 2017 | 10 | 0.030 |
Why?
| Adaptation, Psychological | 1 | 2021 | 547 | 0.030 |
Why?
| Sexual Behavior | 1 | 2021 | 440 | 0.030 |
Why?
| Comorbidity | 1 | 2021 | 1448 | 0.030 |
Why?
| Antibody Specificity | 1 | 2017 | 176 | 0.030 |
Why?
| Capsid Proteins | 1 | 2017 | 69 | 0.030 |
Why?
| Bacterial Infections | 1 | 2018 | 218 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 923 | 0.030 |
Why?
| Inpatients | 1 | 2020 | 380 | 0.030 |
Why?
| Enterovirus | 1 | 2017 | 72 | 0.030 |
Why?
| Pacific Islands | 1 | 2015 | 2 | 0.030 |
Why?
| HEK293 Cells | 1 | 2018 | 591 | 0.030 |
Why?
| Immunization | 1 | 2018 | 397 | 0.030 |
Why?
| Models, Statistical | 1 | 2019 | 599 | 0.030 |
Why?
| Coronavirus Infections | 1 | 2020 | 330 | 0.030 |
Why?
| Hospitals | 1 | 2020 | 581 | 0.030 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 127 | 0.030 |
Why?
| Travel | 1 | 2015 | 121 | 0.030 |
Why?
| Shock | 1 | 2016 | 84 | 0.030 |
Why?
| Blood Vessels | 1 | 2016 | 180 | 0.030 |
Why?
| Capillary Permeability | 1 | 2014 | 139 | 0.030 |
Why?
| Retrospective Studies | 2 | 2021 | 12546 | 0.030 |
Why?
| Antiviral Agents | 1 | 2018 | 645 | 0.030 |
Why?
| Computational Biology | 1 | 2017 | 530 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2017 | 1982 | 0.030 |
Why?
| Rain | 1 | 2013 | 30 | 0.030 |
Why?
| Quality Control | 1 | 2013 | 144 | 0.030 |
Why?
| Cell Line | 1 | 2018 | 2636 | 0.030 |
Why?
| Thrombocytopenia | 1 | 2014 | 177 | 0.030 |
Why?
| Prognosis | 1 | 2020 | 3329 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1262 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2017 | 1177 | 0.020 |
Why?
| Temperature | 1 | 2013 | 565 | 0.020 |
Why?
| Hemorrhage | 1 | 2014 | 620 | 0.020 |
Why?
| Vaccination | 1 | 2017 | 1204 | 0.020 |
Why?
| Databases, Factual | 1 | 2013 | 1125 | 0.020 |
Why?
| Merozoite Surface Protein 1 | 1 | 2007 | 2 | 0.020 |
Why?
| Zimbabwe | 1 | 2007 | 42 | 0.020 |
Why?
| Protozoan Proteins | 1 | 2007 | 62 | 0.020 |
Why?
| Mutation | 1 | 2017 | 3345 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2014 | 1394 | 0.020 |
Why?
| Treatment Outcome | 1 | 2018 | 9088 | 0.020 |
Why?
|
|
Jaenisch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|